Drug intelligence / Profile preview

FREE-005

Development stage: Unknown
Lead developer: Freedom Biosciences
Modality: Small Molecules

Overview

FREE-005 is an undisclosed neuropsychiatric drug candidate currently under development by Freedom Biosciences (Freedom Ventures). The program is part of a pipeline focused on next-generation therapies for mental health and substance use disorders, which includes ketamine-based combinations and 5-HT2A receptor modulators. According to company pipeline projections, FREE-005 was scheduled to enter Phase 1 clinical trials in 2024 following preclinical development in 2023, with a target for Phase 2 development in 2026. Specific details regarding its molecular target and primary indication remain proprietary.

Beyond the preview

Go deeper on FREE-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FREE-005.

Explore the full profile